Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!
by Richard Daverman, PhD
August 19, 2013 -- Wanbang Pharma, a subsidiary of Fosun Pharma, has signed a Letter of Intent to in-license China rights for a diabetes 2 treatment from Sirona Biochem of Canada. The molecule is a member of a new class of oral diabetes drugs known as SGLT2 inhibitors. Wanbang, which will be responsible for obtaining CFDA approval of the drug, will pay up to $9.5 million in upfront and regulatory milestones to Sirona plus royalties, once the drug enters the marketplace. More details....
Stock Symbols: (SHA: 600196; HK: 2196) (TSX: SBM)
Help employers find you! Check out all the jobs and post your resume.
